survivor1x,
That's what should be determined. I don't agree with the way the approval was given, especially for use by all patients which is where I agree completely with flipper44. The approval was given based on very questionable data and the whole process should be investigated from the top down with treatment stopped for those not willing or able to comply with usage directives. In the mean time every patient, doctor and insurance provider should be made immediately aware of the questions with regard to the data to put pressure on FDA to make full unedited data disclosure available.
The elephant in the room seems pretty unresponsive. Getting this and many other messes it represents, as disclosed on this board and elsewhere, cleaned up by patient advocate groups with attorneys and smaller media groups that actually care to organize an awareness campaign might be a good first step. Best wishes.
Market Data 
Markets 
AI
